Pulse Biosciences (PLSE) Accounts Payables (2015 - 2026)

Pulse Biosciences has reported Accounts Payables for 12 years, with the latest figure at $2.8 million in Q2 2026.

• On a quarterly basis, Accounts Payables rose 3.28% year-over-year to $2.8 million in Q2 2026; TTM through Jun 2026 was $2.8 million, a 3.28% increase from a year earlier, with the FY2025 full-year figure at $2.8 million, up 65.99% from the prior year.
• Accounts Payables was $2.8 million for Q2 2026 at Pulse Biosciences, up from $2.8 million in the prior quarter.
• The five-year high for Accounts Payables was $3.5 million in Q1 2022, with the low at $1.4 million in Q3 2023.
• Average Accounts Payables over 5 years is $2.2 million, with a median of $1.9 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables slumped 38.04% in 2023, then jumped 72.44% in 2025.
• Over 5 years, Accounts Payables stood at $1.6 million in 2022, then gained by 16.72% to $1.8 million in 2023, then slipped by 8.88% to $1.7 million in 2024, then surged by 65.99% to $2.8 million in 2025, then advanced by 1.98% to $2.8 million in 2026.
• The last three Accounts Payables figures came in at $2.8 million (Q2 2026), $2.8 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.